Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: A phase I study

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 2, 2003, Pages 207-216

  Bodei, Lisa ^a   Cremonesi, Marta ^a   Zoboli, Stefania ^a   Grana, Chiara ^a   Bartolomei, Mirco ^a   Rocca, Paola ^a   Caracciolo, Maurizio ^a   Mäcke, Helmut R ^b   Chinol, Marco ^a   Paganelli, Giovanni ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

90Y DOTATOC; Peptides; Receptor radiotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; AMINO ACID; ARGININE; LYSINE; OCTREOTIDE[3 TYROSINE]; RADIOISOTOPE; SOMATOSTATIN RECEPTOR; YTTRIUM 90;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INFUSION; DRUG TUMOR LEVEL; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; RADIOISOTOPE THERAPY; TUMOR; VOMITING;

EID: 10744230217     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-1023-y     Document Type: Article

References (28)

1. Hoyer D, Bell GI, Berelowitz M, et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 1995; 16:86-88.
2. Patel YC, Greenwood MT, Panetta R, et al. The somatostatin receptor family. Life Sci 1995; 57:1249-1265.
3. Reisine T, Bell GI: Molecular biology of somatostatin receptors. Endocr Rev 1995; 16:427-442.
4. Lamberts SW, Oosterom R, Neufeld M, et al. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 1985; 60:1161-1165.
5. Plewe G, Beyer J, Krause U, et al. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet 1984; 2:782-784.
6. Lamberts SW. Non-pituitary actions of somatostatin. A review on the therapeutic role of SMS 201-995 (sandostatin). Acta Endocrinol Suppl (Copenh) 1986; 276:41-55.
7. 111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci 1991; 49:1583-1591.
8. Krenning EP, Bakker WH, Kooij PP, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992; 33:652-658.
9. 123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20:716-731.
10. Duncan JR, Stephenson MT, Wu HP, et al. Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res 1997; 57:659-671.
11. 111In-pentetreotide. State of the art and perspectives. Q J Nucl Med 2000; 44:88-95.
12. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999; 26:1439-1447.
13. Smith CM, Liu J, Chen T, et al. Octreo-Ther: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy. Digestion 2000; 62 (Suppl 1):69-72.
14. 90Y-DOTATOC. Eur J Nucl Med 2001; 28: 1552-1554.
15. 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001; 28:426-434.
16. Heppeler A, Froidevaux S, Maecke HR, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur 1999; 7: 1974-1981.
17. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37:538-546.
18. 90Y-DOTATOC. Eur J Nucl Med 1999; 26:877-886.
19. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
20. Perico ME, Chinol M, Nacca A, et al. The humoral immune response to macrocyclic agent DOTA depends on the carrier presentation. J Nucl Med 2001; 42:1697-1703.
21. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001; 12: 941-945.
22. Ferone D, van Hagen PM, Kwekkeboom DJ, et al. Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro. J Clin Endocrinol Metab 2000; 85:1719-1726.
23. 90Y-DOTATOC. Eur J Nucl Med Mol Imaging 2002; 29:435.
24. Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, Mihatsch MJ. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis 2001; 37:847-851.
25. Otte A, Weiner SM, Cybulla M. Is radiation nephropathy caused by yttrium-90? Lancet 2002; 359:979.
26. Bernard BF, Krenning EP, Breeman WA, Rolleman EJ, Bakker WH, Visser TJ, Maecke H, de Jong M. D-Lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997; 38:1929-1933.
27. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998; 25:201-212.
28. Cassady JR: Clinical radiation nephropathy. Int J Radiat Oncol Biol Phys 1995; 31:1249-1256.